A Clinical Study to Evaluate the Efficacy of 3% Niacinamide & Rice Water Toner for skin Brightening

Pureplay Skin Sciences Pvt Ltd1 个研究点分布在 1 个国家目标入组 36 人开始时间: 2025年2月17日最近更新: 2025年9月6日

试验速览

A single Blind One Arm Study

Test Product: 3% Niacinamide & Rice Water Toner

Dose: How to use- Keep eyes closed and spritz toner on cleansed face and neck. Let it air dry. Use twice a day.

Route of Administration: Topical

**Follow ups:**Day 0, Day 3, and Day 7

Assessment Time:

4. Change in Temperature

5. Change in the Moisture content

•Gender: Non-pregnant, non-lactating female aged between 18 to 45 (Female:Male ratio to be 80:20) 2) Subjects willing to give written informed consent 3) Women of child bearing potential must have a negative urine pregnancy test prior to study entry.
•Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events.
•Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial) for the duration of the study.

•1.Subjects who are pregnant, breast-feeding, or planning to become pregnant during the study.
•2.Have any evidence of systemic cancer, squamous cell carcinoma, basal cell carcinoma, in the last 5 years, or any other confounding skin condition.
•3.Have open sores or open lesions in the treatment area(s).
•4.Have any condition that, in the opinion of the investigator, would confound the safety and/or efficacy assessments of the product.
•5.Have participated in any interventional clinical trial in the previous 30 days.
•6.Have a known sensitivity to any of the constituents of the test product including sensitivities to (mention some of active ingredient’s name) 7.Have used, are using, or are planning to use immunosuppressive or immunomodulatory medication (i.e., biologics), including corticosteroids.
•8.Have a history of alcohol or illegal drug/substance abuse, or suspected alcohol or illegal drug/substance abuse in the past 2 years.